Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + nivolumab + pemetrexed
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination involves **carboplatin**, a platinum-based chemotherapy drug; **nivolumab**, a monoclonal antibody that acts as a checkpoint inhibitor; and **pemetrexed**, an antifolate chemotherapy drug. The combination is used in the treatment of non-small cell lung cancer (NSCLC). Carboplatin and pemetrexed work by inhibiting DNA synthesis and cell division, while nivolumab enhances the immune response against cancer cells by blocking the PD-1/PD-L1 pathway.
- Brand names
- Paraplatin + Alimta + Opdivo
- Other names
- carboplatin + pemetrexed + nivolumab
02
Targets
GART (GAR transformylase)DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on carboplatin + nivolumab + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + nivolumab + pemetrexed.